#moderna
moderna
7,551 views
53 Discussing
Hot
Latest
·
--
Bullish
$MRNA is trading at $206.06, rising 5.18%. The biotech stock is gaining attention as investors monitor developments in vaccines, medical research, and the company's future growth opportunities. Further movement will depend on market sentiment and company-specific developments.
$MRNA
{future}(MRNAUSDT)
#Write2Earn! #MRNA #Moderna #BiotechStocks
$MRNA is trading at $206.06, rising 5.18%. The biotech stock is gaining attention as investors monitor developments in vaccines, medical research, and the company's future growth opportunities. Further movement will depend on market sentiment and company-specific developments.
$MRNA
#Write2Earn! #MRNA #Moderna #BiotechStocks
$MRNA
#Write2Earn! #MRNA #Moderna #BiotechStocks
1
283
·
--
【美股盘前异动 - Moderna $MRNAB 】
癌症疫苗三期成功了，莫德纳 $MRNA 两天跌掉四分之一。盘前 184.47 美元、跌 7.81%，距 10 月 21 日的 245.81 回撤 25%。
第一层原因在跟谁比。三期的复发或死亡风险降 42%，二期是 49%；远处转移降 38%，二期是 59%。相对降幅差了 14% 和 36%。数据是正的。比两年前那版弱。
真正卡住的是总生存。HR 0.77，区间 0.45 到 1.31，跨过 1 就等于没证明。停药率 14.0%，单用 Keytruda 是 8.7%，翻了 1.6 倍。疗效更好，代价是更多人退出。
所以卖方没否定疗效。RBC 说临床上有意义、大概率能获批，瑞银说对肾癌膀胱癌更有信心。
下调的是估值：Brookline 把 2030 年 EPS 从 19.11 砍到 18.19，Redburn 直接降到卖出。这只股年内从 29.49 涨到 200 出头，市值里很大一块押在 mRNA 治癌上。下一个变量是 ESMO 的非小细胞肺癌读数：好，这里错杀；糊，25% 只是开始。
{spot}(MRNABUSDT)
#生物科技 #moderna #币安神算子
【美股盘前异动 - Moderna $MRNAB 】
癌症疫苗三期成功了，莫德纳 $MRNA 两天跌掉四分之一。盘前 184.47 美元、跌 7.81%，距 10 月 21 日的 245.81 回撤 25%。
第一层原因在跟谁比。三期的复发或死亡风险降 42%，二期是 49%；远处转移降 38%，二期是 59%。相对降幅差了 14% 和 36%。数据是正的。比两年前那版弱。
真正卡住的是总生存。HR 0.77，区间 0.45 到 1.31，跨过 1 就等于没证明。停药率 14.0%，单用 Keytruda 是 8.7%，翻了 1.6 倍。疗效更好，代价是更多人退出。
所以卖方没否定疗效。RBC 说临床上有意义、大概率能获批，瑞银说对肾癌膀胱癌更有信心。
下调的是估值：Brookline 把 2030 年 EPS 从 19.11 砍到 18.19，Redburn 直接降到卖出。这只股年内从 29.49 涨到 200 出头，市值里很大一块押在 mRNA 治癌上。下一个变量是 ESMO 的非小细胞肺癌读数：好，这里错杀；糊，25% 只是开始。
#生物科技 #moderna #币安神算子
癌症疫苗三期成功了，莫德纳 $MRNA 两天跌掉四分之一。盘前 184.47 美元、跌 7.81%，距 10 月 21 日的 245.81 回撤 25%。
第一层原因在跟谁比。三期的复发或死亡风险降 42%，二期是 49%；远处转移降 38%，二期是 59%。相对降幅差了 14% 和 36%。数据是正的。比两年前那版弱。
真正卡住的是总生存。HR 0.77，区间 0.45 到 1.31，跨过 1 就等于没证明。停药率 14.0%，单用 Keytruda 是 8.7%，翻了 1.6 倍。疗效更好，代价是更多人退出。
所以卖方没否定疗效。RBC 说临床上有意义、大概率能获批，瑞银说对肾癌膀胱癌更有信心。
下调的是估值：Brookline 把 2030 年 EPS 从 19.11 砍到 18.19，Redburn 直接降到卖出。这只股年内从 29.49 涨到 200 出头，市值里很大一块押在 mRNA 治癌上。下一个变量是 ESMO 的非小细胞肺癌读数：好，这里错杀；糊，25% 只是开始。
#生物科技 #moderna #币安神算子
312
·
--
好数据出炉，股价先崩26%：Moderna癌症疫苗，医生说好，钱说不
上周四，Moderna和默克的个性化黑色素瘤疫苗晚期数据公布：1100多名患者，复发或死亡风险降42%，远处转移风险降38%。
分析师说数据“扎实”，可股价盘中一度暴跌26%，创历史最大单日跌幅，市值一度蒸发约240亿美元。
周五再跌1.25%到200.10美元，周一盘前又跌7.3%到185.45美元，盘中才抢回约198美元。
问题不在数据，在预期：今年以来这只股票涨了570%，市场要的是上次小试验的49%，不是42%。
更扎心的是估值：华尔街目标价普遍在104到138美元，高盛刚上调到137美元，Redburn直接给81美元卖出评级。
我觉得这是典型的“利好出尽”：数据不差，但570%的涨幅已经把好消息吃干了，短期就是挤泡沫，观察不追，失效位是日线收回209.59美元上方。
你觉得这是“好数据被错杀”，还是“涨太多活该跌”？
$MRNA $MRK $GS
#Moderna #美股
以上不构成投资建议，DYOR，交易有风险。
好数据出炉，股价先崩26%：Moderna癌症疫苗，医生说好，钱说不
上周四，Moderna和默克的个性化黑色素瘤疫苗晚期数据公布：1100多名患者，复发或死亡风险降42%，远处转移风险降38%。
分析师说数据“扎实”，可股价盘中一度暴跌26%，创历史最大单日跌幅，市值一度蒸发约240亿美元。
周五再跌1.25%到200.10美元，周一盘前又跌7.3%到185.45美元，盘中才抢回约198美元。
问题不在数据，在预期：今年以来这只股票涨了570%，市场要的是上次小试验的49%，不是42%。
更扎心的是估值：华尔街目标价普遍在104到138美元，高盛刚上调到137美元，Redburn直接给81美元卖出评级。
我觉得这是典型的“利好出尽”：数据不差，但570%的涨幅已经把好消息吃干了，短期就是挤泡沫，观察不追，失效位是日线收回209.59美元上方。
你觉得这是“好数据被错杀”，还是“涨太多活该跌”？
$MRNA $MRK $GS
#Moderna #美股
以上不构成投资建议，DYOR，交易有风险。
上周四，Moderna和默克的个性化黑色素瘤疫苗晚期数据公布：1100多名患者，复发或死亡风险降42%，远处转移风险降38%。
分析师说数据“扎实”，可股价盘中一度暴跌26%，创历史最大单日跌幅，市值一度蒸发约240亿美元。
周五再跌1.25%到200.10美元，周一盘前又跌7.3%到185.45美元，盘中才抢回约198美元。
问题不在数据，在预期：今年以来这只股票涨了570%，市场要的是上次小试验的49%，不是42%。
更扎心的是估值：华尔街目标价普遍在104到138美元，高盛刚上调到137美元，Redburn直接给81美元卖出评级。
我觉得这是典型的“利好出尽”：数据不差，但570%的涨幅已经把好消息吃干了，短期就是挤泡沫，观察不追，失效位是日线收回209.59美元上方。
你觉得这是“好数据被错杀”，还是“涨太多活该跌”？
$MRNA $MRK $GS
#Moderna #美股
以上不构成投资建议，DYOR，交易有风险。
287
·
--
Bearish
🚨 $MRNAB DROPS 19.21% IN 24 HOURS! 📉
{spot}(MRNABUSDT)
💰 Price: $194.41
🔴 MRNAB faces heavy selling pressure after falling sharply from recent highs. Can buyers defend $190, or will the decline continue?
📊 BOUNCE BACK OR MORE DOWNSIDE? 👀
💬 BULLISH 🟢 or BEARISH 🔴? Share your prediction!
⚠️ High volatility — manage your risk.
#MRNAB #Moderna #Crypto #Trading
🚨 $MRNAB DROPS 19.21% IN 24 HOURS! 📉
💰 Price: $194.41
🔴 MRNAB faces heavy selling pressure after falling sharply from recent highs. Can buyers defend $190, or will the decline continue?
📊 BOUNCE BACK OR MORE DOWNSIDE? 👀
💬 BULLISH 🟢 or BEARISH 🔴? Share your prediction!
⚠️ High volatility — manage your risk.
#MRNAB #Moderna #Crypto #Trading
💰 Price: $194.41
🔴 MRNAB faces heavy selling pressure after falling sharply from recent highs. Can buyers defend $190, or will the decline continue?
📊 BOUNCE BACK OR MORE DOWNSIDE? 👀
💬 BULLISH 🟢 or BEARISH 🔴? Share your prediction!
⚠️ High volatility — manage your risk.
#MRNAB #Moderna #Crypto #Trading
97
·
--
Moderna 收在242美元，华尔街平均目标价才101，股价是目标价的2.4倍，周六数据前我不追
看见了：周二 Moderna 涨6.7%，盘中243.98创52周新高。
一年前最低收盘才22.36，现在翻了10倍多；8月19日三期初步结果出来，一天涨了177%。
和默沙东合作的黑色素瘤个性化疫苗，完整三期数据10月24日22:30（北京时间）在ESMO公布。
我觉得好消息大半已经在价格里，数据只要不够惊艳，就容易见光死；过去90天公司内部人还卖了约3390万美元股票。
我怎么做：不追，也不提前做空。
数据后站稳243.98再看；跌破10月16日低点208.92，算预期打完。
周六晚数据出来前，你会拿着 Moderna 过周末吗，拿还是不拿？
$MRNA $MRK
#Moderna #癌症疫苗
Moderna 收在242美元，华尔街平均目标价才101，股价是目标价的2.4倍，周六数据前我不追
看见了：周二 Moderna 涨6.7%，盘中243.98创52周新高。
一年前最低收盘才22.36，现在翻了10倍多；8月19日三期初步结果出来，一天涨了177%。
和默沙东合作的黑色素瘤个性化疫苗，完整三期数据10月24日22:30（北京时间）在ESMO公布。
我觉得好消息大半已经在价格里，数据只要不够惊艳，就容易见光死；过去90天公司内部人还卖了约3390万美元股票。
我怎么做：不追，也不提前做空。
数据后站稳243.98再看；跌破10月16日低点208.92，算预期打完。
周六晚数据出来前，你会拿着 Moderna 过周末吗，拿还是不拿？
$MRNA $MRK
#Moderna #癌症疫苗
看见了：周二 Moderna 涨6.7%，盘中243.98创52周新高。
一年前最低收盘才22.36，现在翻了10倍多；8月19日三期初步结果出来，一天涨了177%。
和默沙东合作的黑色素瘤个性化疫苗，完整三期数据10月24日22:30（北京时间）在ESMO公布。
我觉得好消息大半已经在价格里，数据只要不够惊艳，就容易见光死；过去90天公司内部人还卖了约3390万美元股票。
我怎么做：不追，也不提前做空。
数据后站稳243.98再看；跌破10月16日低点208.92，算预期打完。
周六晚数据出来前，你会拿着 Moderna 过周末吗，拿还是不拿？
$MRNA $MRK
#Moderna #癌症疫苗
421
·
--
Bullish
🚨 سيتم إدراج شركة "موديرنا" (Moderna) في مؤشر "ناسداك 100" (Nasdaq 100) بعد أن سجل سهمها ارتفاعاً هائلاً تجاوز 600% في عام 2026.
لقد دفع هذا الصعود القوي شركة "موديرنا" لتصبح واحدة من أبرز الشركات المدرجة في المؤشر، مما يمثل تحولاً جذرياً في مسار الشركة هذا العام.
#stocks #BStocks #الأسهم_الأمريكية #moderna
$MRNAB
{spot}(MRNABUSDT)
🚨 سيتم إدراج شركة "موديرنا" (Moderna) في مؤشر "ناسداك 100" (Nasdaq 100) بعد أن سجل سهمها ارتفاعاً هائلاً تجاوز 600% في عام 2026.
لقد دفع هذا الصعود القوي شركة "موديرنا" لتصبح واحدة من أبرز الشركات المدرجة في المؤشر، مما يمثل تحولاً جذرياً في مسار الشركة هذا العام.
#stocks #BStocks #الأسهم_الأمريكية #moderna
$MRNAB
لقد دفع هذا الصعود القوي شركة "موديرنا" لتصبح واحدة من أبرز الشركات المدرجة في المؤشر، مما يمثل تحولاً جذرياً في مسار الشركة هذا العام.
#stocks #BStocks #الأسهم_الأمريكية #moderna
$MRNAB
1
39
·
--
#ModernaRisesOver12%
Moderna (MRNA) shares shot up more than 12% yesterday, closing at about $67.
Why the big jump?
> The company shared exciting updates on new mRNA treatments for cancer prevention, autoimmune diseases and more.
> Good news from the FDA on their flu vaccine also helped boost confidence.
This is a big win for the biotech company, which has been working hard to expand beyond COVID vaccines. Investors are feeling optimistic about the future!
What do you think — is this the start of something bigger for Moderna?
#Moderna #Stocks #MRNA
#ModernaRisesOver12%
Moderna (MRNA) shares shot up more than 12% yesterday, closing at about $67.
Why the big jump?
> The company shared exciting updates on new mRNA treatments for cancer prevention, autoimmune diseases and more.
> Good news from the FDA on their flu vaccine also helped boost confidence.
This is a big win for the biotech company, which has been working hard to expand beyond COVID vaccines. Investors are feeling optimistic about the future!
What do you think — is this the start of something bigger for Moderna?
#Moderna #Stocks #MRNA
Moderna (MRNA) shares shot up more than 12% yesterday, closing at about $67.
Why the big jump?
> The company shared exciting updates on new mRNA treatments for cancer prevention, autoimmune diseases and more.
> Good news from the FDA on their flu vaccine also helped boost confidence.
This is a big win for the biotech company, which has been working hard to expand beyond COVID vaccines. Investors are feeling optimistic about the future!
What do you think — is this the start of something bigger for Moderna?
#Moderna #Stocks #MRNA
MRNAonAlpha
MRNAUS-0.49%
93
·
--
Bullish
$MRNAB is stabilizing near support levels after a notable pull-back, showing signs of buyer defense around current prices. A successful consolidation here could ignite a relief bounce to challenge upper supply levels.
Target 1: 148.00 Target 2: 152.00 Target 3: 156.00
#MRNAB #Moderna #Crypto
$TUT
{future}(TUTUSDT)
$ZEC
{future}(ZECUSDT)
{spot}(MRNABUSDT)
$MRNAB is stabilizing near support levels after a notable pull-back, showing signs of buyer defense around current prices. A successful consolidation here could ignite a relief bounce to challenge upper supply levels.
Target 1: 148.00 Target 2: 152.00 Target 3: 156.00
#MRNAB #Moderna #Crypto
$TUT
$ZEC
Target 1: 148.00 Target 2: 152.00 Target 3: 156.00
#MRNAB #Moderna #Crypto
$TUT
$ZEC
3
380
·
--
$MRNAon has displayed a powerful initial breakout, pumping over 12% to test a high near 159.42 before encountering quick resistance. Price has since retraced on the 15m chart and is currently forming a tight, low-volatility consolidation range right around the 145.66 level. A successful defense of this base near 142.40 will be crucial for buyers to build momentum for another leg upward.
Target 1: 151.00 Target 2: 159.40 Target 3: 168.00
#MRNAon #Moderna #CryptoTrading #Altcoins
$TRUMP
{future}(TRUMPUSDT)
{alpha}(560x01486675da0764ee780ea7cb65c33062e9b2d28c)
$ZEC
{future}(ZECUSDT)
$MRNAon has displayed a powerful initial breakout, pumping over 12% to test a high near 159.42 before encountering quick resistance. Price has since retraced on the 15m chart and is currently forming a tight, low-volatility consolidation range right around the 145.66 level. A successful defense of this base near 142.40 will be crucial for buyers to build momentum for another leg upward.
Target 1: 151.00 Target 2: 159.40 Target 3: 168.00
#MRNAon #Moderna #CryptoTrading #Altcoins
$TRUMP
$ZEC
Target 1: 151.00 Target 2: 159.40 Target 3: 168.00
#MRNAon #Moderna #CryptoTrading #Altcoins
$TRUMP
$ZEC
1
239
·
--
هذا أمر مذهل. ارتفع سهم شركة "موديرنا" (Moderna) بنحو 150% اليوم، ليقفز إلى المركز الثاني ضمن قائمة الأسهم الأفضل أداءً في مؤشر "إس آند بي 500" (S&P 500) لعام 2026. وبات السهم يحتل هذا الموقع المتميز بمفرده في قائمة تهيمن عليها شركات الذكاء الاصطناعي، ولا يسبقه سوى سهم شركة "سانديسك" (Sandisk).
{stock_us}(MRNA.US)
#stocks #moderna #SNDK #S&P500
{stock_us}(DELL.US)
هذا أمر مذهل. ارتفع سهم شركة "موديرنا" (Moderna) بنحو 150% اليوم، ليقفز إلى المركز الثاني ضمن قائمة الأسهم الأفضل أداءً في مؤشر "إس آند بي 500" (S&P 500) لعام 2026. وبات السهم يحتل هذا الموقع المتميز بمفرده في قائمة تهيمن عليها شركات الذكاء الاصطناعي، ولا يسبقه سوى سهم شركة "سانديسك" (Sandisk).
#stocks #moderna #SNDK #S&P500
#stocks #moderna #SNDK #S&P500
1
105
·
--
Bullish
🚨 MODERNA SURGES 14% AFTER CANCER-THERAPY BREAKTHROUGH 📈
Moderna jumped 14.36% after Moderna and Merck reported positive Phase III results for their personalized mRNA cancer therapy, intismeran autogene, in high-risk melanoma.
🏦 Major banks responded by raising Moderna’s price targets, with Bank of America moving from $40 to $170 and Piper Sandler from $77 to $167.
🎯 TRADING VIEW: BUY 📈
The strong clinical results and major target upgrades create a bullish catalyst, but traders should monitor whether momentum holds after the sharp rally.
❓ Can Moderna extend this breakout? "CLICK ON THE BELOW YELLOW COIN TAG TO GO TO DESIRED TRADING PAGE TO GET BENEFIT TRADE"$MRNA
{future}(MRNAUSDT)
#moderna #MRNAon
🚨 MODERNA SURGES 14% AFTER CANCER-THERAPY BREAKTHROUGH 📈
Moderna jumped 14.36% after Moderna and Merck reported positive Phase III results for their personalized mRNA cancer therapy, intismeran autogene, in high-risk melanoma.
🏦 Major banks responded by raising Moderna’s price targets, with Bank of America moving from $40 to $170 and Piper Sandler from $77 to $167.
🎯 TRADING VIEW: BUY 📈
The strong clinical results and major target upgrades create a bullish catalyst, but traders should monitor whether momentum holds after the sharp rally.
❓ Can Moderna extend this breakout? "CLICK ON THE BELOW YELLOW COIN TAG TO GO TO DESIRED TRADING PAGE TO GET BENEFIT TRADE"$MRNA
#moderna #MRNAon
Moderna jumped 14.36% after Moderna and Merck reported positive Phase III results for their personalized mRNA cancer therapy, intismeran autogene, in high-risk melanoma.
🏦 Major banks responded by raising Moderna’s price targets, with Bank of America moving from $40 to $170 and Piper Sandler from $77 to $167.
🎯 TRADING VIEW: BUY 📈
The strong clinical results and major target upgrades create a bullish catalyst, but traders should monitor whether momentum holds after the sharp rally.
❓ Can Moderna extend this breakout? "CLICK ON THE BELOW YELLOW COIN TAG TO GO TO DESIRED TRADING PAGE TO GET BENEFIT TRADE"$MRNA
#moderna #MRNAon
1
363
·
--
Bullish
Verified
BIO+3.03%
MRNAUS-0.49%
704
·
--
Bullish
قبل ٧ ساعات فقط جلبت لكم خبر رائع سيرفع سهم شركة $MRNA.US وكان السعر حينها 120 $ , وأخبرتكم أنه سيرتفع كما هو موضح 👇 والآن وصل سعر السهم 194 $ 🔥👌🚀🚀
#stocks #MRNA #moderna #Stocks_DAB3
{stock_us}(MRNA.US)
قبل ٧ ساعات فقط جلبت لكم خبر رائع سيرفع سهم شركة $MRNA.US وكان السعر حينها 120 $ , وأخبرتكم أنه سيرتفع كما هو موضح 👇 والآن وصل سعر السهم 194 $ 🔥👌🚀🚀
#stocks #MRNA #moderna #Stocks_DAB3
#stocks #MRNA #moderna #Stocks_DAB3
DAB3_1997
·
--
Bullishسهم $MRNA.US يرتفع بقوة بفضل النتائج الناجحة للقاح ضد سرطان الميلانوما. 💉
#stocks #stoksDAB3 #MRNA
#stocks #stoksDAB3 #MRNA
MRNAUS-0.49%
1
31
·
--
Bullish
قفز سهم شركة "موديرنا" (MRNA) بنسبة 150% - محققاً أفضل أداء يومي في تاريخه - بعد أن أظهر لقاح للسرطان إمكانيةً في منع تكرار الإصابة بالورم الميلانيني. 📈 📈
{stock_us}(MRNA.US)
#stocks #stocksDAB3 #stockDAB3 #moderna
قفز سهم شركة "موديرنا" (MRNA) بنسبة 150% - محققاً أفضل أداء يومي في تاريخه - بعد أن أظهر لقاح للسرطان إمكانيةً في منع تكرار الإصابة بالورم الميلانيني. 📈 📈
#stocks #stocksDAB3 #stockDAB3 #moderna
#stocks #stocksDAB3 #stockDAB3 #moderna
MRNAUS-0.49%
1
43
·
--
Verified
🚨 موديرنا وميرك تعلنان تقدّمًا كبيرًا في لقاح شخصي لعلاج السرطان بتقنية mRNA
في تطور لافت بمجال علاج السرطان، أعلنت شركتا Moderna وMerck عن نتائج إيجابية لتجربة المرحلة الثالثة (Phase 3) للقاح سرطان شخصي يعتمد على تقنية mRNA.
الفكرة مختلفة عن اللقاحات التقليدية:
يتم تصميم اللقاح خصيصًا لكل مريض بناءً على الطفرات الجينية الموجودة داخل الورم، بهدف مساعدة جهاز المناعة على التعرف على الخلايا السرطانية ومهاجمتها بدقة أكبر.
وبحسب الإعلان، شملت الدراسة 1,137 مريضًا بسرطان الجلد عالي الخطورة، وتم استخدام اللقاح مع دواء Keytruda التابع لشركة Merck بعد إزالة الورم جراحيًا.
📌 النتائج المعلنة أظهرت:
• انخفاض خطر عودة السرطان بشكل ملحوظ
• تقليل احتمالية انتشار المرض إلى مناطق أخرى من الجسم
وتأمل Moderna في المضي قدمًا نحو طرح العلاج تجاريًا بعد استكمال الإجراءات التنظيمية اللازمة.
📈 الخبر انعكس بقوة على أسهم الشركتين:
Merck سجلت مستويات قياسية جديدة، بينما قفز سهم Moderna بقوة ووصلت مكاسبه إلى أكثر من 180% خلال موجة الصعود الأخيرة، مع تداول السهم فوق 181 دولارًا في تعاملات ما بعد السوق وفق الأرقام المتداولة مع الخبر.
#Moderna #Merck #MRNA #Cancer #Keytruda #Stocks #Biotech
🚨 موديرنا وميرك تعلنان تقدّمًا كبيرًا في لقاح شخصي لعلاج السرطان بتقنية mRNA
في تطور لافت بمجال علاج السرطان، أعلنت شركتا Moderna وMerck عن نتائج إيجابية لتجربة المرحلة الثالثة (Phase 3) للقاح سرطان شخصي يعتمد على تقنية mRNA.
الفكرة مختلفة عن اللقاحات التقليدية:
يتم تصميم اللقاح خصيصًا لكل مريض بناءً على الطفرات الجينية الموجودة داخل الورم، بهدف مساعدة جهاز المناعة على التعرف على الخلايا السرطانية ومهاجمتها بدقة أكبر.
وبحسب الإعلان، شملت الدراسة 1,137 مريضًا بسرطان الجلد عالي الخطورة، وتم استخدام اللقاح مع دواء Keytruda التابع لشركة Merck بعد إزالة الورم جراحيًا.
📌 النتائج المعلنة أظهرت:
• انخفاض خطر عودة السرطان بشكل ملحوظ
• تقليل احتمالية انتشار المرض إلى مناطق أخرى من الجسم
وتأمل Moderna في المضي قدمًا نحو طرح العلاج تجاريًا بعد استكمال الإجراءات التنظيمية اللازمة.
📈 الخبر انعكس بقوة على أسهم الشركتين:
Merck سجلت مستويات قياسية جديدة، بينما قفز سهم Moderna بقوة ووصلت مكاسبه إلى أكثر من 180% خلال موجة الصعود الأخيرة، مع تداول السهم فوق 181 دولارًا في تعاملات ما بعد السوق وفق الأرقام المتداولة مع الخبر.
#Moderna #Merck #MRNA #Cancer #Keytruda #Stocks #Biotech
في تطور لافت بمجال علاج السرطان، أعلنت شركتا Moderna وMerck عن نتائج إيجابية لتجربة المرحلة الثالثة (Phase 3) للقاح سرطان شخصي يعتمد على تقنية mRNA.
الفكرة مختلفة عن اللقاحات التقليدية:
يتم تصميم اللقاح خصيصًا لكل مريض بناءً على الطفرات الجينية الموجودة داخل الورم، بهدف مساعدة جهاز المناعة على التعرف على الخلايا السرطانية ومهاجمتها بدقة أكبر.
وبحسب الإعلان، شملت الدراسة 1,137 مريضًا بسرطان الجلد عالي الخطورة، وتم استخدام اللقاح مع دواء Keytruda التابع لشركة Merck بعد إزالة الورم جراحيًا.
📌 النتائج المعلنة أظهرت:
• انخفاض خطر عودة السرطان بشكل ملحوظ
• تقليل احتمالية انتشار المرض إلى مناطق أخرى من الجسم
وتأمل Moderna في المضي قدمًا نحو طرح العلاج تجاريًا بعد استكمال الإجراءات التنظيمية اللازمة.
📈 الخبر انعكس بقوة على أسهم الشركتين:
Merck سجلت مستويات قياسية جديدة، بينما قفز سهم Moderna بقوة ووصلت مكاسبه إلى أكثر من 180% خلال موجة الصعود الأخيرة، مع تداول السهم فوق 181 دولارًا في تعاملات ما بعد السوق وفق الأرقام المتداولة مع الخبر.
#Moderna #Merck #MRNA #Cancer #Keytruda #Stocks #Biotech
1
590
#ModernaRisesOver12%
🚨 Wall Street Wasn't Watching... Until Modern$MRNAon Exploded +12%!
In a market where most investors were focused on AI and crypto, Moderna suddenly stole the spotlight with a double-digit rally.
Why are institutional investors suddenly paying attention again?
Is this the start of a biotech comeback... or are traders chasing a short-term headline?
One thing is clear: when a mega-cap biotech moves this fast, the entire healthcare sector starts getting watched.
👇 What's your prediction?
🟢 Rally continues
🔴 Profit-taking starts
🟡 Too early to tell
#ModernaRisesOver12 #Moderna #Stocks
$SPCXB
{spot}(SPCXBUSDT)
$MRNAon
{alpha}(560x01486675da0764ee780ea7cb65c33062e9b2d28c)
#ModernaRisesOver12%
🚨 Wall Street Wasn't Watching... Until Modern$MRNAon Exploded +12%!
In a market where most investors were focused on AI and crypto, Moderna suddenly stole the spotlight with a double-digit rally.
Why are institutional investors suddenly paying attention again?
Is this the start of a biotech comeback... or are traders chasing a short-term headline?
One thing is clear: when a mega-cap biotech moves this fast, the entire healthcare sector starts getting watched.
👇 What's your prediction?
🟢 Rally continues
🔴 Profit-taking starts
🟡 Too early to tell
#ModernaRisesOver12 #Moderna #Stocks
$SPCXB
$MRNAon
🚨 Wall Street Wasn't Watching... Until Modern$MRNAon Exploded +12%!
In a market where most investors were focused on AI and crypto, Moderna suddenly stole the spotlight with a double-digit rally.
Why are institutional investors suddenly paying attention again?
Is this the start of a biotech comeback... or are traders chasing a short-term headline?
One thing is clear: when a mega-cap biotech moves this fast, the entire healthcare sector starts getting watched.
👇 What's your prediction?
🟢 Rally continues
🔴 Profit-taking starts
🟡 Too early to tell
#ModernaRisesOver12 #Moderna #Stocks
$SPCXB
$MRNAon
1
133
·
--
Article
STOCKS | Moderna Surges 50% Premarket, Merck Gains 5.6%Moderna (MRNA.O) experienced a remarkable surge of 50% in premarket trading, according to Jin10, reflecting investor optimism and strong market confidence. The biotech company’s shares jumped significantly ahead of the regular trading session, signaling a major rally driven by positive developments or market sentiment.
Meanwhile, Merck (MRK.N) also saw a notable increase, gaining 5.6% in premarket, suggesting broader strength in the healthcare sector. The gains for Merck, although more moderate compared to Moderna, indicate a favorable outlook for pharmaceutical giants amid ongoing industry developments or recent news catalysts.
The sharp rise in Moderna’s stock price is noteworthy, as such a substantial move in premarket activity often indicates investor anticipation of upcoming earnings reports, positive clinical trial results, or strategic corporate announcements. The market reaction underscores the high level of interest and speculation surrounding biotech stocks in the current trading environment.
These movements in Moderna and Merck stocks are being closely watched by traders and investors, as they could influence broader market dynamics and sector sentiment. The biotech sector remains volatile and sensitive to news, making these premarket surges significant signals for the day’s trading activity. #Moderna #Merck #BiotechStocks
STOCKS | Moderna Surges 50% Premarket, Merck Gains 5.6%
Moderna (MRNA.O) experienced a remarkable surge of 50% in premarket trading, according to Jin10, reflecting investor optimism and strong market confidence. The biotech company’s shares jumped significantly ahead of the regular trading session, signaling a major rally driven by positive developments or market sentiment.
Meanwhile, Merck (MRK.N) also saw a notable increase, gaining 5.6% in premarket, suggesting broader strength in the healthcare sector. The gains for Merck, although more moderate compared to Moderna, indicate a favorable outlook for pharmaceutical giants amid ongoing industry developments or recent news catalysts.
The sharp rise in Moderna’s stock price is noteworthy, as such a substantial move in premarket activity often indicates investor anticipation of upcoming earnings reports, positive clinical trial results, or strategic corporate announcements. The market reaction underscores the high level of interest and speculation surrounding biotech stocks in the current trading environment.
These movements in Moderna and Merck stocks are being closely watched by traders and investors, as they could influence broader market dynamics and sector sentiment. The biotech sector remains volatile and sensitive to news, making these premarket surges significant signals for the day’s trading activity. #Moderna #Merck #BiotechStocks
Meanwhile, Merck (MRK.N) also saw a notable increase, gaining 5.6% in premarket, suggesting broader strength in the healthcare sector. The gains for Merck, although more moderate compared to Moderna, indicate a favorable outlook for pharmaceutical giants amid ongoing industry developments or recent news catalysts.
The sharp rise in Moderna’s stock price is noteworthy, as such a substantial move in premarket activity often indicates investor anticipation of upcoming earnings reports, positive clinical trial results, or strategic corporate announcements. The market reaction underscores the high level of interest and speculation surrounding biotech stocks in the current trading environment.
These movements in Moderna and Merck stocks are being closely watched by traders and investors, as they could influence broader market dynamics and sector sentiment. The biotech sector remains volatile and sensitive to news, making these premarket surges significant signals for the day’s trading activity. #Moderna #Merck #BiotechStocks
1
160
Moderna 股价单日暴涨 124%,只因一项癌症疫苗三期临床试验传来捷报。对于一家曾因新冠红利退潮而估值持续承压的 mRNA 公司来说,这份数据无异于一场"诺曼底登陆"。
从产业角度看,这意味着 mRNA 技术平台在传染病之外的肿瘤领域完成了首次大规模验证。如果后续能拿下 FDA 审批,Moderna 将从一家"卖疫苗的公司"蜕变为多管线生物科技平台,估值逻辑也要彻底重写。华尔街显然也看到了这层叙事切换,所以才给出了超百点的夸张涨幅。
但 124% 这样的暴涨,本身就是双刃剑。它意味着预期已经被快速打满,后续任何审评节奏的延后、二三期数据分歧,都可能引发剧烈回吐。再加上生物科技股历来波动率远超大盘,追高者要格外留意仓位控制。
回到加密市场,这种风险偏好回升对生物科技概念代币、mRNA 主题 RWA,乃至整体 risk-on 情绪都是正面信号;不过真正能受益的链上资产并不多,还是别硬蹭。
你怎么看这波 Moderna 的狂欢,是真突破还是情绪透支?
#Moderna #癌症疫苗 #美股
Moderna 股价单日暴涨 124%,只因一项癌症疫苗三期临床试验传来捷报。对于一家曾因新冠红利退潮而估值持续承压的 mRNA 公司来说,这份数据无异于一场"诺曼底登陆"。
从产业角度看,这意味着 mRNA 技术平台在传染病之外的肿瘤领域完成了首次大规模验证。如果后续能拿下 FDA 审批,Moderna 将从一家"卖疫苗的公司"蜕变为多管线生物科技平台,估值逻辑也要彻底重写。华尔街显然也看到了这层叙事切换,所以才给出了超百点的夸张涨幅。
但 124% 这样的暴涨,本身就是双刃剑。它意味着预期已经被快速打满,后续任何审评节奏的延后、二三期数据分歧,都可能引发剧烈回吐。再加上生物科技股历来波动率远超大盘,追高者要格外留意仓位控制。
回到加密市场,这种风险偏好回升对生物科技概念代币、mRNA 主题 RWA,乃至整体 risk-on 情绪都是正面信号;不过真正能受益的链上资产并不多,还是别硬蹭。
你怎么看这波 Moderna 的狂欢,是真突破还是情绪透支?
#Moderna #癌症疫苗 #美股
从产业角度看,这意味着 mRNA 技术平台在传染病之外的肿瘤领域完成了首次大规模验证。如果后续能拿下 FDA 审批,Moderna 将从一家"卖疫苗的公司"蜕变为多管线生物科技平台,估值逻辑也要彻底重写。华尔街显然也看到了这层叙事切换,所以才给出了超百点的夸张涨幅。
但 124% 这样的暴涨,本身就是双刃剑。它意味着预期已经被快速打满,后续任何审评节奏的延后、二三期数据分歧,都可能引发剧烈回吐。再加上生物科技股历来波动率远超大盘,追高者要格外留意仓位控制。
回到加密市场,这种风险偏好回升对生物科技概念代币、mRNA 主题 RWA,乃至整体 risk-on 情绪都是正面信号;不过真正能受益的链上资产并不多,还是别硬蹭。
你怎么看这波 Moderna 的狂欢,是真突破还是情绪透支?
#Moderna #癌症疫苗 #美股
21
·
--
Verified
🚨 THIS IS WHY $MRNA.US IS EXPLODING! 📈
Moderna just dropped positive Phase 3 results for its personalized mRNA cancer therapy with Merck’s KEYTRUDA.
The trial showed significant improvements in recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in melanoma patients.
And the market reacted HARD:
$MRNA: +140% 🚀🔥
Personalized mRNA cancer vaccines just took a massive step forward. 🧬💉
#MRNA #moderna #CancerCure #StocksTalks
🚨 THIS IS WHY $MRNA.US IS EXPLODING! 📈
Moderna just dropped positive Phase 3 results for its personalized mRNA cancer therapy with Merck’s KEYTRUDA.
The trial showed significant improvements in recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in melanoma patients.
And the market reacted HARD:
$MRNA: +140% 🚀🔥
Personalized mRNA cancer vaccines just took a massive step forward. 🧬💉
#MRNA #moderna #CancerCure #StocksTalks
Moderna just dropped positive Phase 3 results for its personalized mRNA cancer therapy with Merck’s KEYTRUDA.
The trial showed significant improvements in recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in melanoma patients.
And the market reacted HARD:
$MRNA: +140% 🚀🔥
Personalized mRNA cancer vaccines just took a massive step forward. 🧬💉
#MRNA #moderna #CancerCure #StocksTalks
MRNAUS-0.49%
373
🚨 $MRNAB
{spot}(MRNABUSDT)
— BINANCE bSTOCKS LAUNCH IN 35 MINUTES! 🔥
$MRNAB is a tokenized bStock providing economic exposure to Moderna, with 24/7 trading and 1:1 conversion rights to the underlying share, subject to applicable rules.
⏳ Launch: ~35 minutes
📊 Stock Reference: $150.58
⚡ Volatility could spike around launch and the first candle.
👀 Watch: Wait for the first candle close and clear direction instead of chasing the opening move.
DYOR • NFA
#MRNAB #Moderna #Binance #bStocks
🚨 $MRNAB
— BINANCE bSTOCKS LAUNCH IN 35 MINUTES! 🔥
$MRNAB is a tokenized bStock providing economic exposure to Moderna, with 24/7 trading and 1:1 conversion rights to the underlying share, subject to applicable rules.
⏳ Launch: ~35 minutes
📊 Stock Reference: $150.58
⚡ Volatility could spike around launch and the first candle.
👀 Watch: Wait for the first candle close and clear direction instead of chasing the opening move.
DYOR • NFA
#MRNAB #Moderna #Binance #bStocks
— BINANCE bSTOCKS LAUNCH IN 35 MINUTES! 🔥
$MRNAB is a tokenized bStock providing economic exposure to Moderna, with 24/7 trading and 1:1 conversion rights to the underlying share, subject to applicable rules.
⏳ Launch: ~35 minutes
📊 Stock Reference: $150.58
⚡ Volatility could spike around launch and the first candle.
👀 Watch: Wait for the first candle close and clear direction instead of chasing the opening move.
DYOR • NFA
#MRNAB #Moderna #Binance #bStocks
70
Log in to explore more content
Join global crypto users on Binance Square
⚡️ Get latest and useful information about crypto.
💬 Trusted by the world’s largest crypto exchange.
👍 Discover real insights from verified creators.
Email / Phone number
Trending Topics
1
#CanMicrosoftDeliverOnAI
459,332 views
3,353 Discussing
2
#CanGoogleDefindItsCore
284,170 views
2,369 Discussing
3
#EarningsSeason
6M views
29,470 Discussing
4
#$10.9BBitcoinOptionsExpireFriday
1,886 views
74 Discussing
5
#ThailandSupremeCourtRulesBitcoinIsProperty
10,292 views
316 Discussing
6
#BitcoinSurpasses$81K
34,670 views
117 Discussing
7
#RobinhoodFalls8.4%AfterItsResults
20,576 views
363 Discussing
8
#KOSPISurges6.63%BackAbove6000
19,571 views
355 Discussing
9
#DatavaultAICantWithdrawBitcoinFromBiconomy
23,803 views
333 Discussing
10
#FOMCWatch
9.4M views
29,807 Discussing